Prometheus Files For $100M IPO

San Diego-based Prometheus Laboratories, a specialty pharmaceutical company focused on detection, diagnosis and treatment of gastrointestinal diseases and disorders, said Wednesday in a filing with the SEC that it is looking to raise up to $100M in an IPO. The IPO is being underwritten by Goldman, Sachs & Co. , Credit Suisse, Banc of America Securities, Cowen and Company, and Pacific Growth Equities. Prometheus is backed by DLJ Merchant Banking, Split Rock, Sprout Capital, Apax Partners, Wachovia Capital, Brentwood Venture Capital, and others.